The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Osiris Therapeutics Inc

Nasdaq: OSIR
Last

(U.S.) $14.35

Today's change-0.13 -0.90%
Updated December 19 10:56 AM -5GMT. Delayed by at least 15 minutes.
 

Osiris Therapeutics Inc

Nasdaq: OSIR
Last

(U.S.) $14.35

Today's change-0.13 -0.90%
Updated December 19 10:56 AM -5GMT. Delayed by at least 15 minutes.

Reversal following new 50-day high

Osiris Therapeutics Inc is lower today, dropping (U.S.)$0.13 or 0.90% to (U.S.)$14.35 after setting a new 50-day high. Over the last five days, shares have gained 11.07%, but are down 10.76% for the last year to date. Shares have underperformed the S&P 500 by 21.90% during the last year.

Key company metrics

  • Open(U.S.) $14.57
  • Previous close(U.S.) $14.48
  • High(U.S.) $14.98
  • Low(U.S.) $14.10
  • Bid / Ask(U.S.) $14.28 / (U.S.) $14.36
  • YTD % change-10.76%
  • Volume74,665
  • Average volume (10-day)93,412
  • Average volume (1-month)82,781
  • Average volume (3-month)99,677
  • 52-week range(U.S.) $11.80 to (U.S.) $18.41
  • Beta1.13
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.08
Updated December 19 10:56 AM -5GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-5.23%

Osiris Therapeutics Inc has a net profit margin of -5.23%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.58%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue1713108
Total other revenue--------
Total revenue1713108
Gross profit131086
Total cost of revenue4322
Total operating expense16131111
Selling / general / administrative11986
Research & development1112
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total0000
Operating income10-1-3
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax1-1-1-3
Income after tax1-1-1-1
Income tax, total000-1
Net income1-2-150
Total adjustments to net income--------
Net income before extra. items1-1-1-1
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1-1-1-1
Inc. avail. to common incl. extra. items1-2-150
Diluted net income1-2-150
Dilution adjustment----00
Diluted weighted average shares35343433
Diluted EPS excluding extraordinary itemsvalue per share0.02-0.04-0.02-0.04
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share0.02-0.04-0.02-0.04